Doxa AB (SE:DOXA)
:DOXA
Want to see SE:DOXA full AI Analyst Report?
Top Page
Doxa AB
(DOXA)
Select Model
Select Model
Rating:54Neutral
Price Target:
kr0.45
▲(3.18% Upside)
Action:ReiteratedDate:04/24/26
The score is held back primarily by very weak profitability and large ongoing losses despite strong TTM revenue growth and improved cash flow. Technicals are moderately supportive (above key short/mid-term averages with positive MACD), but valuation signals are unfavorable due to the loss-making profile and no dividend yield data.
Positive Factors
Strong revenue growth
Sustained TTM revenue growth of +27.7% indicates the company is expanding sales and market penetration. Over a 2–6 month horizon this growth supports scale advantages, higher absolute cash generation potential, and increases the chance incremental investments will pay off once margins improve.
Negative Factors
Severe net losses
A TTM net loss of -316.4M demonstrates the business is not yet profitable and is consuming capital. Persistently negative margins erode equity and limit the firm's ability to self-fund growth, increasing dependence on external financing or dilution unless profitable trends emerge.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong revenue growth
Sustained TTM revenue growth of +27.7% indicates the company is expanding sales and market penetration. Over a 2–6 month horizon this growth supports scale advantages, higher absolute cash generation potential, and increases the chance incremental investments will pay off once margins improve.
Read all positive factors
Doxa AB (DOXA) vs. iShares MSCI Sweden ETF (EWD)
Market Cap
kr540.57M
Dividend YieldN/A
Average Volume (3M)738.50K
Price to Earnings (P/E)―
Beta (1Y)0.35
Revenue Growth175.00%
EPS Growth81.46%
CountrySE
Employees5
SectorReal Estate
Sector Strength53
IndustryMedical - Instruments & Supplies
Share Statistics
EPS (TTM)-0.02
Shares Outstanding1,285,530,600
10 Day Avg. Volume416,677
30 Day Avg. Volume738,495
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)0.29
Price to Sales (P/S)8.91
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Doxa AB Business Overview & Revenue Model
Company Description
Doxa AB (publ), a dental company, develops, manufactures, and commercializes bioceramic dental products under the Ceramir brand worldwide. It offers Crown & Bridge, a dental cement that is used for permanent cementing of crowns and bridges. The co...
How the Company Makes Money
null...
Doxa AB Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
46
Neutral
Cash Flow
60
Neutral
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 81.10M | 63.50M | 15.50M | 9.90M | 5.20M | 10.90M |
| Gross Profit | -154.40M | -158.40M | 15.50M | 9.90M | 5.20M | 7.90M |
| EBITDA | -42.00M | -46.80M | -1.70B | 296.00M | -39.80M | 77.20M |
| Net Income | -316.40M | -335.50M | -1.72B | 291.90M | -39.90M | 76.20M |
Balance Sheet | ||||||
| Total Assets | 4.02B | 4.03B | 8.20B | 3.50B | 1.79B | 878.80M |
| Cash, Cash Equivalents and Short-Term Investments | 57.50M | 58.20M | 70.60M | 111.90M | 60.00M | 15.10M |
| Total Debt | 1.41B | 1.36B | 3.63B | 256.50M | 4.90M | 0.00 |
| Total Liabilities | 2.07B | 2.06B | 5.89B | 280.80M | 18.30M | 9.00M |
| Stockholders Equity | 1.95B | 1.97B | 2.31B | 3.22B | 1.77B | 869.80M |
Cash Flow | ||||||
| Free Cash Flow | 119.60M | 0.00 | -63.60M | -37.80M | -39.40M | -18.60M |
| Operating Cash Flow | 350.80M | -15.80M | -63.20M | -37.80M | -38.50M | -18.60M |
| Investing Cash Flow | -177.80M | -25.50M | -834.90M | -205.10M | -267.30M | -392.90M |
| Financing Cash Flow | -321.20M | 36.20M | 807.70M | 294.70M | 350.70M | 422.10M |
Doxa AB Technical Analysis
Positive
0.44
Price Trends
0.42
Positive
0.44
Positive
0.47
Negative
Market Momentum
<0.01
Negative
58.02
Neutral
63.80
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:DOXA, the sentiment is Positive. The current price of 0.44 is above the 20-day moving average (MA) of 0.41, above the 50-day MA of 0.42, and below the 200-day MA of 0.47, indicating a neutral trend. The MACD of <0.01 indicates Negative momentum. The RSI at 58.02 is Neutral, neither overbought nor oversold. The STOCH value of 63.80 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SE:DOXA.
Doxa AB Peers Comparison
UnderperformOutperform
Sector (65)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
65 Neutral | $2.17B | 12.19 | 3.79% | 4.94% | 3.15% | 1.96% | |
54 Neutral | kr540.57M | -6.14 | -35.70% | ― | 175.00% | 81.46% | |
51 Neutral | kr6.17M | -0.91 | ― | ― | ― | ― | |
48 Neutral | kr81.84M | -0.67 | -572.32% | ― | -8.89% | 80.71% | |
45 Neutral | kr668.69M | -6.71 | ― | ― | ― | -20.77% | |
42 Neutral | kr314.69M | -0.91 | -108.15% | ― | 369.86% | 84.86% |
* Real Estate Sector Average
SE:DOXA
Doxa AB
0.42
-0.04
-7.69%
SE:S2M
S2Medical AB Class B
0.01
>-0.01
-9.09%
SE:LCLEAN
LifeClean International AB
0.08
-0.17
-68.65%
SE:QLINEA
Q-linea AB
16.90
-16.71
-49.72%
SE:FLUO
FluoGuide A/S
40.90
0.20
0.49%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.